

74331\96741

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rakoczy et al.

: Appl. Ref.:

GRI-010

Serial. No: 09/065,082

: Examiner:

S. McGarry

Filing Date: 3 Aug. 1999

: Group Art Unit:

1635

For:

**HYALURONIC ACID AS DNA CARRIER FOR GENE THERAPY AND VEGF
ANTISENSE DNA TO TREAT ABNORMAL RETINAL VASCULARIZATION**


DECLARATION

Assistant Commissioner of Patents & Trademarks
Washington, DC 20231

Sir/Madam:

I, Viviana Amzel, hereby state that the contents of the paper and computer readable copies of the enclosed Sequence Listing section submitted herewith and of the sequences contained in the originally filed US patent application, the Australian and PCT priority applications, and the amendments made with the responses filed in the PCT phase (copies were enclosed with the papers filed with documents at the time of entering the US National Phase) are substantially the same. The enclosed Sequence Listing (paper and computerized forms) include no significant new matter and the sequences therein, to the best of applicant's knowledge, are substantially the same as the sequences in the original Australian, PCT and US patent applications as filed, and the amendments entered during the PCT phase.

Respectfully submitted.
ARTER & HADDEN



Viviana Amzel, Ph. D.
Agent for Applicant

Citicorp Building
725 South Figueroa St.
Suite 3400
213-430-3520 Ph.
213-617-9255 Fax

I hereby certify that this paper or fee is being deposited with the United States Postal Service "First Class Mail" service under 37 CFR 1.8 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington DC 20231, on October 22, 1999, by Mary Helen Lopez.


SIGNATURE

h:\Griffith Hack\010\dec seq.doc
368419

RECEIVED
NOV 1 1999
TECH CENTER 1600/2900

PATENT

GAU 1635

BOX SEA

RECEIVED
TECH CENTER 1600/2900
99 NOV -1 AM 11:23

